Conference
Part 1 Results of a dose finding study of Belantamab Mafodotin (GSK2857916) in combination with Pomalidomide (POM) and Dexamethasone (DEX) for the treatment of Relapsed/Refractory Multiple Myeloma
Authors
Trudel S; McCurdy A; Sutherland H; Louzada M; Venner C; White D; Kotb R; Mian H; Camacho F; Fu M
Publication Date
November 5, 2021
Name of conference
American Society of Hematology (ASH) Annual Meeting and Exposition
Conference place
Virtual
Conference start date
December 2, 2020
Conference end date
December 11, 2020